SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 8 SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 9 3. TRIAL DESIGN Table 1: Trial Design A Study design This is a first in man, open label, multi -centre, Phase I trial to investigate the safety, immunogenicity and patient survival following administration of the AST -VAC2 vaccine . Only one target dose (1× 107 cells) will be explored.